Acadia Healthcare enters the back half of August in an unusual spot: a stock that has fallen nearly half its value year-to-date is suddenly bouncing hard, yet short sellers — who hold one of the larger positions in the healthcare sector — are only modestly reducing their bets.
The most striking dynamic this week is the gap between price action and short-side conviction. The stock gained 8.8% on the week and 4% on Tuesday alone, closing at $29.87. That is a meaningful move. But short interest, at 22.3% of the free float, has pulled back only 7.8% over the same period — from roughly 21.9 million shares to 20.5 million. Shorts are not covering aggressively. They are trimming around the edges of a position that remains, by any measure, large. The ORTEX short score of 70.5 — down from 73.5 a week ago but still elevated — reflects exactly that: pressure easing, not reversing.
The borrow market sends a different signal. Availability has loosened sharply, climbing from around 127% to 171% over the past week, meaning roughly 1.7 shares are available to borrow for every share already short. That is approaching the loosest level seen in recent months, with the 52-week low in availability sitting at 57.6%. Cost to borrow has barely moved, holding near 0.5% — essentially free by any short-selling standard. Together, these conditions make it easy and cheap to add or maintain a short position, which may explain why covering has been so measured. There is no mechanical pressure forcing shorts out. Options positioning has ticked slightly more defensive, with the put/call ratio at 0.66, about 1.6 standard deviations above its 20-day mean of 0.61 — cautious, but not extreme.
The Street's view is constructive but anchored by uncertainty about the business rather than the technicals. Following the Q2 earnings beat at the end of July, analysts at Guggenheim raised their target to $39 and Barclays lifted theirs to $32, both maintaining existing ratings. The broader analyst cluster has been moving targets up through the summer — UBS, TD Cowen, and Keybanc all raised in July — leaving a consensus mean target near $33, a thin premium to the current price. The bull case rests on Acadia's positioning in behavioural health, where demand remains structurally robust and the company has shown it can grow admissions and expand margins. The bear case is harder to dismiss: reimbursement pressure, payor denials, regulatory scrutiny, and a cost structure that leaves limited cushion if volume disappoints. EPS momentum scores well on 30- and 90-day readings (81st and 74th percentiles respectively), but EPS surprise sits at just the 20th percentile — the company's track record of beating estimates is not strong, which keeps a lid on conviction.
Institutional positioning adds a notable layer. BlackRock added 3.3 million shares as of July 31, lifting its stake to 16% — by far the largest disclosed position. Farallon Capital built a fresh 4.2 million share position in Q2, adding 2.5 million shares last quarter, and Dimensional added 1.4 million. These are meaningful accumulations, suggesting that at the right price, fundamental buyers see value. But Greenlight and Abrams Bison were modest net sellers over the same period, and the insider tape has been consistently one-directional: EVP Brian Farley has sold small tranches on four separate occasions since February, the most recent in late July at $34.51. No purchases have been filed by any insider in the visible history.
The next formal test is the Q3 earnings print, scheduled for November 2. The recent earnings history is worth noting without reading too much into it: the Q2 report in late July produced an 8.3% one-day gain and a 12.3% five-day rally, but immediately prior to that, the stock fell 15.8% on an earnings date. The swings have been large in both directions. With the stock now trading roughly 10% below analyst mean targets after a week of recovery, the question heading into autumn is whether the short base — still at 22% of float and largely unmoved despite the bounce — begins to see covering as a tactical necessity, or whether loosening borrow conditions simply allow it to sit comfortably through the next catalyst.
See the live data behind this article on ORTEX.
Open ACHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
